TG Therapeutics Pulls Ukoniq/Ublitiximab Combo Applications Due To Adverse Survival Trend

 
• By Sue Sutter
  
Shovel in dirt
FDA has 'dug in' on the adverse survival trends seen with PI3K inhibitors, TG Therapeutics says. • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers